A therapeutic atlas of monogenic inflammatory bowel disease
Genetic testing can match people with rare inflammatory bowel disease to tailored treatments based on their specific genetic mutations.
Evidence-based, mechanism-guided therapies are urgently needed for treating monogenic inflammatory bowel disease (mIBD). The reported conclusion is: This study highlights the potential of precision medicine approaches tailored to genetic and pathway-specific mechanisms, while underscoring the urgent need for effective therapies in many monogenic conditions that remain without established treatment options.
What the study was
- Study design
- Systematic review
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Journal of Crohn's & colitis
Why it surfaced
Retained for Precision oncology and genomic medicine; score reflects the available PubMed abstract, study design, clinical relevance, and unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.